Blood and Marrow Transplant Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada; Research & Development, Canadian Blood Services, Toronto, Ontario, Canada; Transfusion Medicine Laboratory, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Transfusion. 2014 Mar;54(3):681-90. doi: 10.1111/trf.12329. Epub 2013 Jul 5.
Hemolysis may follow intravenous immunoglobulin (IVIG), with product, dosing, and host factors contributing. The importance of recipient features remains unclear.
A 52-year-old obese woman, 10 years after ABO-mismatched (recipient O, donor A) marrow transplantation, presented with immune thrombocytopenia (ITP). IVIG at 100 g/day × 2 days was followed by hemoglobinuria and angina and dyspnea, with frank hemoglobinemia and anemia (hemoglobin 12.9 to 8.4 over 24 hr, to a nadir of 6.9 g/dL).
Serologic methods established ABO, A1, Lewis, and Secretor type, while monocyte monolayer assay (MMA) examined erythrophagocytosis with control or patient monocytes, and the implicated IVIG lot to opsonize control (group A1, A2, B, O) or patient red blood cells (RBCs). Baseline, hemolytic, and convalescent markers (including cytokines) were assessed.
Passive anti-A was identified on reverse type and eluted from sensitized RBCs (immunoglobulin G 1+, C3d-). Le(a-b+) typing and saliva confirmed H Secretor status. MMA revealed significant activity between patient RBCs, monocytes, and IVIG. However, normal A1 cells opsonized with IVIG were not significantly phagocytosed by either normal or patient monocytes. Proinflammatory markers were significantly elevated before and after IVIG.
Synergizing host factors (including obesity-unadjusted dosing and existing inflammation) marked this severe post-IVIG hemolytic crisis. Group A antigen restriction to myeloid tissues, with H Secretor phenotype, may have contributed, rendering this bone marrow transplant chimera vulnerable to anti-A in a manner analogous to the idiosyncratic effect of therapeutic anti-D in certain D+ ITP recipients. However, MMA suggested a macrophage activation state as contributory, perhaps precipitated by existing inflammation.
静脉注射免疫球蛋白(IVIG)后可能会发生溶血,产品、剂量和宿主因素都会导致溶血。受者特征的重要性尚不清楚。
一名 52 岁肥胖女性,在 ABO 不相容(受者 O,供者 A)骨髓移植后 10 年,因免疫性血小板减少症(ITP)就诊。接受 100 g/天×2 天的 IVIG 治疗后,出现血红蛋白尿、心绞痛和呼吸困难,血红蛋白明显升高,出现贫血(24 小时内血红蛋白从 12.9 降至 8.4,最低降至 6.9 g/dL)。
血清学方法确定 ABO、A1、Lewis 和 Secretor 血型,单核细胞单层分析(MMA)检测用对照或患者单核细胞吞噬红细胞的情况,并检测相关 IVIG 批次与对照(A1、A2、B、O)或患者红细胞(RBC)结合的情况。评估基线、溶血性和恢复期标志物(包括细胞因子)。
在反向定型中发现了被动抗-A,从致敏的 RBC 中洗脱出来(免疫球蛋白 IgG1+,C3d-)。Le(a-b+) 分型和唾液证实 H Secretor 表型。MMA 显示患者 RBC、单核细胞和 IVIG 之间存在显著活性。然而,用 IVIG 包被的正常 A1 细胞并没有被正常或患者单核细胞显著吞噬。在 IVIG 前后,促炎标志物显著升高。
宿主因素(包括未调整剂量的肥胖和现有炎症)协同作用,导致这例严重的 IVIG 后溶血性危机。骨髓移植嵌合体中组织受限的 A 抗原,伴 H Secretor 表型,可能是导致该嵌合体易发生抗-A 的原因,类似于某些 D+ ITP 受者中治疗性抗-D 的独特作用。然而,MMA 提示巨噬细胞激活状态可能是一个促成因素,可能是由现有炎症引起的。